Pyrazinamide: Clinical Trials

31 trials of Pyrazinamide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 4 not yet recruiting, 4 recruiting, 3 active not recruiting. 31 Phase 3, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 331Completed 16, Not yet recruiting 4, Recruiting 4, Active not recruiting 3, Unknown 3, Withdrawn 1
Phase 26Completed 5, Active not recruiting 1

Follow Pyrazinamide: new trials by email Literature Review of Pyrazinamide trials Research Report on Pyrazinamide

Trials (filtered) newest first · largest first

All 31 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)
Isoniazid (H), Rifampicin (R), Pyrazinamide (Z) - Tuberculosis (TB)
Phase 3RecruitingUniversity College, London7842026-10-122026-10-26
A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis
MDR-END Plus regimen, Standard-of-care (SoC) treatment - Rifampicin-Resistant Tuberculosis
Phase 3Not yet recruitingSeoul National University Hospital2942026-10-012026-06-30
Ultra-Short Regimen for Elderly DS-TB
Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis
Phase 3Not yet recruitingShenzhen Third People's Hospital3002025-07-252025-07-22
A PAN-USR TB Multi-Center Trial
Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis
Phase 3RecruitingShenzhen Third People's Hospital6102025-06-182025-12-01
Shortened Regimen for Drug-susceptible TB in Children
Isoniazid, Rifampin, Pyrazinamide - Tuberculosis, Tuberculosis, Pulmonary
Phase 3RecruitingJohns Hopkins University8602025-01-152026-11-12
Intensified Short Course Regimen for TBM in Adults
High dose rifampicin (25mg/kg), Moxifloxacin 400mg, Aspirin 150 mg - Tuberculous Meningitis
Phase 3Not yet recruitingIndian Council of Medical Research3722024-03-012023-12-21
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis:Contezolid, Delamanid and Bedaquiline Cohort
Bedaquiline, Delamanid, Contezolid - Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
Phase 3Active not recruitingBeijing Chest Hospital1862023-12-222025-04-01
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
Rifabutin, Delamanid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis Infection
Phase 2 / Phase 3Active not recruitingCenters for Disease Control and Prevention2882023-11-212026-09-21
Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
Sitafloxacin, SMZ/TMP, Rifampin - Tuberculosis, Pulmonary
Phase 3UnknownFirst Affiliated Hospital of Zhejiang University6202022-10-012022-07-12
Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis
Rifampin, Levofloxacin, Rifampicin, Pyrazinamide, Ethambutol and Isoniazid - Disseminated Tuberculosis, HIV
Phase 3Active not recruitingUniversity of Cape Town7322021-08-112026-01-06
Novel Triple-dose Tuberculosis Retreatment Regimen
6EH³R³Z, 6EHRZ - Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis
Phase 3RecruitingInstitute of Tropical Medicine, Belgium3702021-03-012025-04-13
Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)
Atorvastatin with standard anti tuberculosis drugs, Standard anti tuberculosis drugs only - Tuberculosis, Pulmonary, Tuberculosis
Phase 2 / Phase 3CompletedObafemi Awolowo University Teaching Hospital1502021-01-192023-12-08
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
High-dose rifampicin, Isoniazid, Pyrazinamide - Tuberculosis, Pulmonary
Phase 3Not yet recruitingSeoul National University Hospital9262020-09-012020-07-24
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
Pretomanid, Bedaquiline, Moxifloxacin - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Phase 2 / Phase 3CompletedGlobal Alliance for TB Drug Development4552018-07-302026-08-27
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
Rifampicin, Isoniazid, Pyrazinamide - Tuberculosis, Pulmonary
Phase 2 / Phase 3CompletedUniversity College, London6752018-03-212023-08-14
Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin
Delamanid, Linezolid, Levofloxacin - Tuberculosis Multi Drug Resistant Active
Phase 3WithdrawnBoston University2017-08-012017-09-11
A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis
Rifampicin, Isoniazid, Ethambutol - Pulmonary Tuberculosis
Phase 3CompletedSt George's, University of London6722017-02-012023-04-27
Evaluating Newly Approved Drugs for Multidrug-resistant TB
Bedaquiline, Delamanid, Clofazimine - Tuberculosis, Multidrug-Resistant, Infection, Bacterial
Phase 3CompletedMédecins Sans Frontières, France7542016-12-012025-02-10
The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline), Moxifloxacin, Clofazimine - MDR-TB
Phase 3CompletedIUATLD, Inc5882016-03-012023-09-28
Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis
Rifapentine, Moxifloxacin, Rifampin - Tuberculosis
Phase 3CompletedCenters for Disease Control and Prevention25162016-01-252026-08-27

Showing 20 of 31. Sign in to see all of them.

Conditions studied

Tuberculosis (17)  ·  Tuberculosis, Pulmonary (16)  ·  Tuberculosis, Multidrug-Resistant (8)  ·  HIV Infections (4)  ·  Acquired Immunodeficiency Syndrome (3)  ·  AIDS-Related Opportunistic Infections (1)  ·  Bacterial Infections (1)  ·  Extensively Drug-Resistant Tuberculosis (1)  ·  Infections (1)  ·  Latent Tuberculosis (1)  ·  Lung Diseases (1)  ·  Mycobacterium Infections (1)  ·  Respiratory Tract Diseases (1)  ·  Respiratory Tract Infections (1)  ·  Tuberculosis, Lymph Node (1)

Sponsors

Global Alliance for TB Drug Development (3)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (3)  ·  Centers for Disease Control and Prevention (2)  ·  Seoul National University Hospital (2)  ·  Shenzhen Third People's Hospital (2)  ·  Tuberculosis Research Centre, India (2)  ·  University College, London (2)  ·  University of Cape Town (2)  ·  All India Institute of Medical Sciences (1)  ·  Beijing Chest Hospital (1)  ·  Boston University (1)  ·  First Affiliated Hospital of Zhejiang University (1)  ·  French National Agency for Research on AIDS and Viral Hepatitis (1)  ·  Huashan Hospital (1)  ·  IUATLD, Inc (1)

Countries

South Africa (11)  ·  India (9)  ·  Uganda (9)  ·  China (4)  ·  Georgia (4)  ·  Philippines (4)  ·  Brazil (3)  ·  Malaysia (3)  ·  Pakistan (3)  ·  Tanzania (3)  ·  United States (3)  ·  Zambia (3)  ·  Indonesia (2)  ·  Kenya (2)  ·  Mozambique (2)

Top investigators

A K Jain, MBBS FICA (1)  ·  Alexander Pym, MB BMRCP PhD (1)  ·  Ali Zumla, BSc MBChB MSc PhD (1)  ·  Amina Jindani, MD (1)  ·  Andreas Diacon, BM MD (1)  ·  Andrew Nunn, BSc MSc (1)  ·  Andrew Nunn, PhD (1)  ·  Angela Crook (1)  ·  Anjula Bhargava, MS (1)  ·  Arun Aggarwal, MD (1)  ·  Ashish Rohatgi, DTCD (1)  ·  Ashok K Singh, MD, FCCP, FCCS (1)  ·  Aziah Mahayiddin, MD (1)  ·  Bhanu P Singh, MD, FCCP (1)  ·  Bolanle A Omotoso, MD (1)

Results publications

PMID 36808186, PMID 17928422, PMID 19542476, PMID 19965813, PMID 21813327, PMID 22116143, PMID 23317958, PMID 23433590, PMID 24099345, PMID 24663014, PMID 25196020, PMID 26038418, PMID 26104205, PMID 26847437, PMID 26929418, PMID 29507938, PMID 29779774, PMID 30102705, PMID 30157391, PMID 30865791, PMID 31676905, PMID 31932382, PMID 34563240, PMID 34691079, PMID 35028659, PMID 35175905, PMID 35978342, PMID 36053506, PMID 36546625, PMID 37567554, PMID 37980911, PMID 37986887, PMID 38320155, PMID 38462751, PMID 38468320, PMID 38693583, PMID 38720383, PMID 38768617, PMID 39343425, PMID 39879593, PMID 40414233, PMID 40915316